CD38 Knockout Natural Killer Cells Expressing an Affinity Optimized CD38 Chimeric Antigen Receptor Successfully Target Acute Myeloid Leukemia with Reduced Effector Cell Fratricide

Researchers developed a CD38 CAR-NK cell therapy for acute myeloid leukemia, first by using an NK cell line which had low baseline CD38 expression and subsequently NK cells expanded from healthy donors.